Marino I R, Todo S, Tzakis A G, Klintmalm G, Kelleher M, Iwatsuki S, Starzl T E, Esquivel C O
Department of Surgery, University Health Center of Pittsburgh, Pennsylvania.
Cancer. 1988 Nov 15;62(10):2079-84. doi: 10.1002/1097-0142(19881115)62:10<2079::aid-cncr2820621002>3.0.co;2-j.
Ten patients received liver transplants for unresectable epithelioid hemangioendothelioma (EHE). At the time of transplantation, four patients had microscopic metastases to the hilar lymph nodes, and one of the four also had metastases to a rib. The fifth patient had metastases to the lung, pleura, and diaphragm. The remaining five patients were believed to be free of metastatic disease. Two of these five patients died of metastatic disease at 3 and 16 months, respectively, after transplantation. Interestingly, all five patients with metastatic involvement are currently alive 40.6 +/- 22 months (mean +/- standard error of mean [SEM]) after transplantation, although one of these patients currently has metastatic disease to the lungs and mediastinum. Thus, the projected 5-year actuarial survival rate is 76%, with two patients at risk after the third year. In conclusion, liver transplantation is a reasonable procedure for bulky, otherwise unresectable, EHE even in the presence of metastatic disease.
10例患者因无法切除的上皮样血管内皮瘤(EHE)接受了肝移植。移植时,4例患者有肝门淋巴结微小转移,其中1例还伴有肋骨转移。第5例患者有肺、胸膜和膈肌转移。其余5例患者被认为无转移性疾病。这5例患者中有2例分别在移植后3个月和16个月死于转移性疾病。有趣的是,所有5例有转移累及的患者目前在移植后40.6±22个月(平均±平均标准误差[SEM])仍存活,尽管其中1例患者目前有肺和纵隔转移。因此,预计5年精算生存率为76%,第三年后有2例患者处于危险状态。总之,即使存在转移性疾病,肝移植对于体积较大、否则无法切除的EHE来说也是一种合理的手术方式。